PPARG and pancreatic neoplasm: Studies have shown that rosiglitazone-induced radiosensitivity in pancreatic cancer is achieved by increasing the expression and nuclear translocation of PPARγ, which is related to the abnormal lipid metabolism caused by the PPARγ-induced upregulation of FABP4 [176].